1. Home
  2. BAK vs SGMT Comparison

BAK vs SGMT Comparison

Compare BAK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

N/A

Current Price

$1.82

Market Cap

713.3M

Sector

Industrials

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$8.95

Market Cap

648.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BAK
SGMT
Founded
1972
2006
Country
Brazil
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
713.3M
648.1M
IPO Year
2002
2021

Fundamental Metrics

Financial Performance
Metric
BAK
SGMT
Price
$1.82
$8.95
Analyst Decision
Sell
Buy
Analyst Count
6
12
Target Price
$1.90
★ $27.91
AVG Volume (30 Days)
★ 1.7M
1.2M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,000,000.00
Revenue This Year
$7.44
N/A
Revenue Next Year
$4.41
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.40
$4.50
52 Week High
$5.40
$11.45

Technical Indicators

Market Signals
Indicator
BAK
SGMT
Relative Strength Index (RSI) 53.50 39.87
Support Level $1.40 $8.69
Resistance Level $2.16 $9.37
Average True Range (ATR) 0.11 0.67
MACD 0.04 -0.15
Stochastic Oscillator 82.47 16.05

Price Performance

Historical Comparison
BAK
SGMT

About BAK Braskem SA ADR

Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: